Literature DB >> 23644508

New potential cell source for hepatocyte transplantation: discarded livers from metabolic disease liver transplants.

Roberto Gramignoli1, Veysel Tahan, Kenneth Dorko, Kristen J Skvorak, Marc C Hansel, Wenchen Zhao, Raman Venkataramanan, Ewa C S Ellis, Carl Jorns, Bo-Goran Ericzon, Staffan Rosenborg, Raoul Kuiper, Kyle A Soltys, George V Mazariegos, Ira J Fox, Elizabeth M Wilson, Markus Grompe, Stephen C Strom.   

Abstract

UNLABELLED: Domino liver transplantation is a method used to increase the number of liver grafts available for orthotopic liver transplantation (OLT). Reports indicate that livers from patients with metabolic liver disease can be safely transplanted into select recipients if the donor's defect and the recipient's metabolic needs are carefully considered. The liver of patients with many types of metabolic liver disease is morphologically and biochemically normal, except for the mutation that characterizes that disease. Other biochemical functions normally performed by the liver are present and presumably "normal" in these hepatocytes. Hepatocytes were isolated from the liver of 35 organ donors and 35 liver tissues taken at OLT from patients with liver disease were analyzed for 9 different measures of viability and function. The data indicate that cells isolated from some diseased livers performed as well or better than those isolated from organ donors with respect to viability, cell yield, plating efficiency and in assays of liver function, including drug metabolism, conjugation reactions and ammonia metabolism. Cells from metabolic diseased livers rapidly and efficiently repopulated a mouse liver upon transplantation.
CONCLUSIONS: As with domino liver transplantation, domino cell transplantation deserves consideration as method to extend the pool of available organs and cells for transplantation.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23644508      PMCID: PMC4262521          DOI: 10.1016/j.scr.2013.03.002

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  26 in total

Review 1.  The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.

Authors:  Ronald N Hines; D Gail McCarver
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

2.  Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience.

Authors:  George V Mazariegos; D Holmes Morton; Rakesh Sindhi; Kyle Soltys; Navdeep Nayyar; Geoffrey Bond; Diana Shellmer; Benjamin Shneider; Jerry Vockley; Kevin A Strauss
Journal:  J Pediatr       Date:  2011-08-11       Impact factor: 4.406

Review 3.  The European experience.

Authors:  Leo Roels; Axel Rahmel
Journal:  Transpl Int       Date:  2011-01-26       Impact factor: 3.782

Review 4.  Domino liver transplantation: how far can we push the paradigm?

Authors:  Irinel Popescu; Simona O Dima
Journal:  Liver Transpl       Date:  2012-01       Impact factor: 5.799

5.  One liver for four children: first clinical series of liver cell transplantation for severe neonatal urea cycle defects.

Authors:  Jochen Meyburg; Anibh M Das; Friederike Hoerster; Martin Lindner; Heinz Kriegbaum; Guido Engelmann; Jan Schmidt; Michael Ott; Andrea Pettenazzo; Thomas Luecke; Harald Bertram; Georg F Hoffmann; Alberto Burlina
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

6.  Hepatocyte transplantation for glycogen storage disease type Ib.

Authors:  Kwang-Woong Lee; Ji-Hyun Lee; Sung Wook Shin; Sung Joo Kim; Jae Won Joh; Doo-Hoon Lee; Jong-Won Kim; Hwa-Young Park; Soo-Youn Lee; Hwan Hyo Lee; Jin Wan Park; Shi-Yeon Kim; Hee-Hoon Yoon; Doo-Hee Jung; Yon Ho Choe; Suk-Koo Lee
Journal:  Cell Transplant       Date:  2007       Impact factor: 4.064

7.  Liver cell transplantation: basic investigations for safe application in infants and small children.

Authors:  Jochen Meyburg; Krassimira Alexandrova; Marc Barthold; Sabine Kafert-Kasting; Andrea S Schneider; Masoumeh Attaran; Friederike Hoerster; Jan Schmidt; Georg F Hoffmann; Michael Ott
Journal:  Cell Transplant       Date:  2009-09-28       Impact factor: 4.064

8.  Domino liver transplantation.

Authors:  Henryk E Wilczek; Marie Larsson; Shinji Yamamoto; Bo-Göran Ericzon
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-04-06

9.  Domino liver transplantation: risks and benefits.

Authors:  B-G Ericzon; M Larsson; H E Wilczek
Journal:  Transplant Proc       Date:  2008-05       Impact factor: 1.066

10.  Isolation of primary human hepatocytes from normal and diseased liver tissue: a one hundred liver experience.

Authors:  Ricky H Bhogal; James Hodson; David C Bartlett; Christopher J Weston; Stuart M Curbishley; Emma Haughton; Kevin T Williams; Gary M Reynolds; Phillip N Newsome; David H Adams; Simon C Afford
Journal:  PLoS One       Date:  2011-03-29       Impact factor: 3.240

View more
  21 in total

1.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01

2.  Hepatocyte Transplantation.

Authors:  Ira J Fox
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

3.  Hepatocyte Transplantation in Special Populations: Clinical Use in Children.

Authors:  Zahida Khan; Stephen C Strom
Journal:  Methods Mol Biol       Date:  2017

4.  Domino hepatocyte transplantation using explanted human livers with metabolic defects attenuates D-GalN/LPS-induced acute liver failure.

Authors:  Guang-Peng Zhou; Shi-Peng Li; Yi-Zhou Jiang; Jie Sun; Yu-Le Tan; Zhi-Gui Zeng; Lin Wei; Wei Qu; Li-Ying Sun; Zhi-Jun Zhu
Journal:  J Transl Med       Date:  2022-10-20       Impact factor: 8.440

Review 5.  Liver-humanized mice: A translational strategy to study metabolic disorders.

Authors:  Yonghong Luo; Haocheng Lu; Daoquan Peng; Xiangbo Ruan; Yuqing Eugene Chen; Yanhong Guo
Journal:  J Cell Physiol       Date:  2021-10-18       Impact factor: 6.513

Review 6.  The Use of Induced Pluripotent Stem Cells for the Study and Treatment of Liver Diseases.

Authors:  Marc C Hansel; Julio C Davila; Massoud Vosough; Roberto Gramignoli; Kristen J Skvorak; Kenneth Dorko; Fabio Marongiu; William Blake; Stephen C Strom
Journal:  Curr Protoc Toxicol       Date:  2016-02-01

7.  Clinical Hepatocyte Transplantation: What Is Next?

Authors:  James E Squires; Kyle A Soltys; Patrick McKiernan; Robert H Squires; Stephen C Strom; Ira J Fox; Alejandro Soto-Gutierrez
Journal:  Curr Transplant Rep       Date:  2017-10-14

8.  Humanized liver mouse model with transplanted human hepatocytes from patients with ornithine transcarbamylase deficiency.

Authors:  Go Sugahara; Chihiro Yamasaki; Ami Yanagi; Suzue Furukawa; Yuko Ogawa; Akinari Fukuda; Shin Enosawa; Akihiro Umezawa; Yuji Ishida; Chise Tateno
Journal:  J Inherit Metab Dis       Date:  2020-12-30       Impact factor: 4.982

Review 9.  Human Hepatocytes Isolated from Explanted Livers: A Powerful Tool to Understand End-stage Liver Disease and Drug Screening.

Authors:  Lanuza A P Faccioli; Zehra N Kocas-Kilicarslan; Ricardo Diaz-Aragon; Takashi Motomura; Sriram Amirneni; Michelle R Malizio; Michael C Coard; Carla Frau; Nils Haep; Rodrigo M Florentino; Alina Ostrowska
Journal:  Organogenesis       Date:  2021-10-02       Impact factor: 2.316

10.  Hepatocytes buried in the cirrhotic livers of patients with biliary atresia proliferate and function in the livers of urokinase-type plasminogen activator-NOG mice.

Authors:  Hiroshi Suemizu; Kazuaki Nakamura; Kenji Kawai; Yuichiro Higuchi; Mureo Kasahara; Junichiro Fujimoto; Akito Tanoue; Masato Nakamura
Journal:  Liver Transpl       Date:  2014-08-04       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.